Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer.

Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. Urology. 2011 Mar; 77(3):682-7.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.